Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors

NCT03755739 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Guangzhou Medical University as lead sponsor.

NCT NCT03755739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03755739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Trial of Comparison of Benefit of Administration of Checkpoint Inhibitors Plus Chemodrug Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University
Phase
Phase 2/3
Overall status
Recruiting
Start date
November 1, 2018
Completion date
November 1, 2036
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cervical cancer, colo-rectal cancer, head and neck cancer, hepatocarcinoma, lung cancer, melanoma, ovarian cancer, pancreas cancer, renal cancer